CCN5/WISP-2: A micromanager of breast cancer progression Sushanta K. BanerjeeSnigdha Banerjee Review 10 April 2012 Pages: 63 - 71
CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis Véronique OuelletPeter M. Siegel Review Open access 18 March 2012 Pages: 73 - 85
Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells Logan A. WalshMario A. CepedaSashko Damjanovski Research Article 08 January 2012 Pages: 87 - 95
Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis Bruce L. RiserNarasimharao BhagavathulaJames Varani Research Article 31 May 2012 Pages: 97 - 105
A proposal of an in vitro model which mimics in situ areas of carcinoma Elizabeth F. MartinezPollyanna T. MontaldiVera C. de Araújo Report 16 February 2012 Pages: 107 - 109
Egr-ly awaiting a “personalized medicine” approach to treat scleroderma Andrew Leask Bits and Bytes 15 February 2012 Pages: 111 - 113
CCN3: a novel anti-fibrotic treatment in end-stage renal disease? Andrew Leask Bits and Bytes 16 March 2012 Pages: 115 - 116
CCN3: the-pain-killer inside me Bernard PerbalInternational CCN Society Bits and Bytes 30 March 2012 Pages: 117 - 120